Nucala (mepolizumab) and Dupixent (dupilumab) are brand-name subcutaneous ... which is mixed with sterile water to form a solution given as a subcutaneous injection • solution inside a prefilled ...

Sitryx CEO Iain Kilty describes the biopharmaceutical industry effort to go beyond immunosuppression in autoimmune and ...

We believe our oral medicines can provide a differentiated and potentially better solution, oral drugs with ... to what has been reported for dupilumab. Though as we have said, we believe the ...

Dupilumab had a fivefold improvement in sustained disease remission in bullous pemphigoid compared with placebo, along with a significant reduction in oral corticosteroid use.

More than 1,000,000 patients are being treated with Dupixent globally. 1 Dupilumab is being jointly developed by Regeneron and Sanofi under a global collaboration agreement. To date, dupilumab has ...

The table is a review of notable updates that occurred in February 2025 for investigational products in development.

BLA accepted for review Dupilumab (Regeneron and Sanofi) Interleukin-4 receptor alpha antagonist Treatment of adults with bullous pemphigoid. sBLA accepted for Priority Review Rezpegaldesleukin ...

Memoirs, interviews and essays now widely celebrate “going no contact” with a parent. The New York Times published this, just a day ago: ”I Broke Up With My Abusive Mother. I Don't Regret ...

TikTok is preparing to sunset its creator marketplace in favor of a new, more expanded experience, the company has informed businesses and creators via email. The online platform, which connects ...

(RTTNews) - Regeneron Pharmaceuticals Inc. (REGN) and Sanofi presented positive results from the pivotal ADEPT Phase 2/3 trial evaluating the investigational use of Dupixent (dupilumab) in adults ...

Including these FQHCs lessons in the toolkit will allow providers to form better understandings and solutions when engaging with patients often underserved in health care settings, noted AAPA.